Article Text
Neurological dilemmas
Switching patients at high risk of PML from natalizumab to another disease-modifying therapy
Abstract
There are several options for switching people with multiple sclerosis (MS) who are at high risk of developing progressive multifocal leukoencephalopathy (PML) from natalizumab to alemtuzumab. However, some of these have risks that need to be managed, for example, the risks of carrying over asymptomatic PML from natalizumab on to the new therapy, and the risk of rebound disease activity associated with a prolonged washout after starting natalizumab. We propose a pragmatic bridging strategy, using another disease-modifying therapy (DMT), to reduce the risk of switching from natalizumab to alemtuzumab. We also discuss the caveats and subtleties associated with sequencing DMTs in MS and the complex decision making involved.
- MULTIPLE SCLEROSIS
- Alemtuzumab
- Natalizumab
- PML
- progressive multifocal leukoencephalopathy
Statistics from Altmetric.com
Linked Articles
- Editors' commentary
Read the full text or download the PDF:
Other content recommended for you
- Multiple sclerosis and the risk of infection: Association of British Neurologists consensus guideline
- Update on disease-modifying therapies for multiple sclerosis
- Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications
- Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring
- Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events
- Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group
- Disease modifying therapies for relapsing multiple sclerosis
- Disease-modifying therapies for multiple sclerosis
- JC viral loads in patients with Crohn’s disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?
- Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis